Contact

Write to us about a pilot, a demo or a collaboration.

Fill in the form with the product you are interested in and a short note on your institution's needs. We reply by email.

Process

  1. STEP 01

    Clinical needs review

    Together we map the target wards, your current medication safety processes and your clinical pharmacy workflow.

  2. STEP 02

    Retrospective test protocol (LOI)

    The validation protocol on anonymised past prescriptions, and its success criteria, are set out in a non-binding Letter of Intent (LOI).

  3. STEP 03

    Integration and live validation

    Under an ethics-approved study, the system is connected to your hospital information system over HL7 FHIR R4 and validated in the real workflow under clinician supervision.

Pilot protocol and LOI framework

Email

Please do not send patient data or other special categories of personal data through our contact channels.

Product of interest
Plain text. Please do not share patient data.0/2000

When you press Send, your request goes directly to [email protected].

Pilot protocol

Pilot protocol and LOI framework.

The Letter of Intent (LOI) we sign with hospital management is based on this framework. The details are written together with the institution; this page is not binding.

Purpose and scope

Purpose
Validate the product on the institution's own data against an independent reference.
Phase A · Retrospective
Anonymised past prescription or claim data is assessed against an expert panel that has not seen the system's output.
Phase B · Shadow mode
The system assesses live data but shows nothing to physicians or specialists. Its findings are compared with the actual decisions afterwards.
Phase C · Live pilot
Optional. With ethics committee and institutional approval, alerts are shown to users on a limited ward.
Duration and wards
Agreed with the institution and written into the LOI.

Security and KVKK

Deployment
On the institution's own servers (on-prem) or in an isolated VPC dedicated to it. Data does not leave the institution's infrastructure.
Anonymisation
Identifiers are anonymised in real time as data enters the system.
Access
Role-based. The LavieuxLabs team has no access to identifiable data.
Legal basis
Ethics committee approval, a data processing agreement and the safeguards required by Article 12 of KVKK (Turkey's data protection law).
Logging
Every assessment and every access is written to an append-only log.

Measured outcomes

Accuracy · Phase A
Sensitivity, specificity and positive predictive value.
Events detected · Phases A–B
Share of the potential adverse drug events identified by the panel that the system also detected.
Alert burden · Phase B
Alerts per 100 prescriptions.
Physician response · Phase C
Time from alert to decision, and the rate of overrides with a documented reason.
Report
Performance report shared with the institution; input to the MDR clinical evaluation file.

In Shield pilots, the measures are the rejection rate, the rejection reasons caught at pre-check and specialist review time, not adverse drug events. In no phase does the system make a decision in place of the user.

Location

We are on the Konya Technical University campus.

If you would like to visit, please book an appointment by email first.

R&D campus

Konya Technical University

Faculty of Engineering and Natural Sciences

Akademi Mah. Yeni İstanbul Cad. No: 363/6
42250 Selçuklu / Konya, Türkiye
Get directions in Google Maps

The map is provided by Google.

Loading the map sends data such as your IP address to Google, and Google may set cookies. Details: Cookie Policy